Key Highlights from EV-302 Study at ESMO 2023 : vimarsana.co

Expert insight into the data presented at ESMO 2023 on the EV-302 study of enfortumab vedotin and pembrolizumab in the management of locally advanced or metastatic urothelial carcinoma.

Related Keywords

, Sia Daneshmand , Radical Cystectomy , Metastatic Disease , Chemo Radiation , Platinum Based Therapies , Gemcitabine , Cisplatin , Carboplatin , Jesmo , Ev 302 Study , Open Label , Randomized Study , Enfortumab Vedotin In Combination , Pembrolizumab , Chemotherapy , Platinum Based Therapy , Standard Of Care , First Line Setting , Guidelines ,